OssDsign Expands VA Hospital Access to Bone Graft Product

OssDsign AB has been awarded a new U.S. Department of Veteran Affairs (VA) contract that covers approximately 100 additional VA orthopedic hospitals nationwide, boosting the company’s penetration of the U.S. military market.
 
The new contract is a continuation of OssDsign’s collaboration with Red One Medical, a medical technology private sector representative to the U.S. government that identifies medical innovations for the VA and Department of Defense (DoD). The Distribution and Pricing Agreement (DAPA) the company forged in 2021 has gradually been expanded. OssDsign’s latest contract covers all VA orthopedic hospitals nationwide, essentially giving all current and retired military personnel access to its bone graft product, OssDsign Catalyst.
 
“From the beginning of our entry into orthobiologics, we have been highly focused on building access to hospitals throughout the U.S., including active military and veteran hospitals, and we are honored to have the opportunity to provide treatment solutions for an even larger part of America’s veterans and military staff. This new contract signifies another important step in improving our access to the U.S. market as well as a deepened access of our military contract,” OssDsign CEO Morten Henneveld said.
 
The Veterans Health Administration (VHA) is the largest U.S. integrated healthcare system, with nearly 1,300 healthcare facilities serving 9 million veterans throughout America. 
 
OssDsign Catalyst is a nanosynthetic bone graft that stimulates healthy bone tissue formation in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure that is resorbed and replaced by new and healthy bone tissue in the body. Twelve-month results from the TOP FUSION clinical study, published in the Biomedical Journal of Scientific & Technical Research, show a 93 % spinal fusion rate as well as improvements in quality of life and pain after surgery with OssDsign Catalyst.
 
Red One is a government-certified service-disabled veteran-owned small business and disability-owned business enterprise that connects medical and pharmaceutical manufacturers to VA and DoD hospitals. 
 
OssDsign develops and provides next-generation orthobiologics products. Based on cutting-edge material science, the company develops and markets products that support the body’s own healing capabilities, giving patients back the life they deserve. The company has a strong U.S. market presence and its stock is traded on Nasdaq First North Growth Market in Stockholm, Sweden.